Prevalence of bone pain decreases as lymph node stage increases in nonsmall cell lung cancer patients.


Journal

Current problems in cancer
ISSN: 1535-6345
Titre abrégé: Curr Probl Cancer
Pays: United States
ID NLM: 7702986

Informations de publication

Date de publication:
02 2019
Historique:
received: 20 02 2018
revised: 23 07 2018
accepted: 17 08 2018
pubmed: 10 9 2018
medline: 12 5 2020
entrez: 10 9 2018
Statut: ppublish

Résumé

According to lung cancer guidelines, positron emission tomography scan is recommended for initial evaluation of bone metastasis. However, guidelines differ in their recommendations for when it should be used. We investigated the appropriate use of bone imaging in nonsmall cell lung cancer (NSCLC) patients. One hundred seventy-seven consecutive NSCLC patients who had distant metastases at presentation and were admitted between January 2012 and April 2016 were retrospectively reviewed. Among patients with bone metastases, we explored bone pain, number of bone metastases, location of bone metastases, and clinical tumor (T) and lymph node (N) classification. Sixty-three patients had bone metastases. There was a trend toward an increase in prevalence of bone metastases as lymph node stage increased. The prevalence of bone pain significantly decreased as N stage increased (p = 0.017). N0 and N2-3 patients were more likely to have multiple bone metastases (p = 0.038). Compared with patients who had a single bone metastasis, patients with multiple metastases had a significantly higher probability of having at least 1 bone metastasis located in the thorax or upper abdomen. All N0 patients have at least 1 bone metastasis in the thorax or upper abdomen. Clinical N0 NSCLC patients with bone metastasis are likely to have bone pain and have multiple bone metastases. N2-3 patients are more likely to have bone metastases but less likely to have bone pain. If NSCLC patients do not have bone pain, and CT of the chest and upper abdomen does not reveal any lymph node or bone metastasis, further survey for bone metastases may be omitted; bone imaging should be performed in N2 and N3 patients regardless of symptoms.

Identifiants

pubmed: 30195805
pii: S0147-0272(18)30039-4
doi: 10.1016/j.currproblcancer.2018.08.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

86-91

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Minako Saito (M)

Department of Respiratory Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Hidenori Kage (H)

Department of Respiratory Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. Electronic address: kageh-tky@umin.ac.jp.

Takahiro Ando (T)

Department of Respiratory Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Ryoko Sawada (R)

Department of Orthopaedic Surgery, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Yosuke Amano (Y)

Department of Respiratory Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Yasushi Goto (Y)

Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.

Yusuke Shinoda (Y)

Department of Orthopaedic Surgery, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Takahide Nagase (T)

Department of Respiratory Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH